Department of Physiological Sciences, School of Medicine, University of Zambia, Lusaka, Zambia.
Department of Obstetrics and Gynaecology, School of Medicine, University of Zambia, Lusaka, Zambia.
Pan Afr Med J. 2024 Jul 25;48:136. doi: 10.11604/pamj.2024.48.136.42683. eCollection 2024.
pre-eclampsia affects an estimated 8% of pregnant women and contributes to over 12% of global maternal deaths. High-sensitivity C-reactive protein (hs-CRP) is a potential marker of pre-eclampsia. However, little is known about hs-CRP levels in women with pre-eclampsia in Zambia. This study examined whether hs-CRP levels differ between women who develop pre-eclampsia compared with controls overall and in subgroups of women living with and without HIV.
a case-control study was conducted among 40 pregnant women who developed preeclampsia (cases) and 40 normotensive pregnant women (controls) living with (n=20) and without HIV (n=20) at women and newborn hospital from February to May 2022. Standard ELISA kits were used to determine hs-CRP levels. The conditional logistic regression model calculated the odds ratios for hs-CRP and other predictor variables with their 95% confidence intervals.
the median hs-CRP levels were higher among the cases than controls (7.84mg/ml vs 6.13mg/ml, p<0.001). Similar hs-CRP levels were observed among pre-eclamptic women living with HIV on antiretroviral therapy (ART) compared to HIV-negative women (7.92mg/ml vs 7.17mg/ml, p=0.862). On the other hand, normotensive women living with HIV on ART had different hs-CRP levels than HIV-negative women (6.60mg/ml vs 3.96mg/ml, p<0.001). Multivariable conditional logistic regression showed that pregnant women with higher levels of hs-CRP (AOR=1.01, 95% CI=1.01, 1.01) were more likely to have pre-eclampsia after adjusting for significant predictors. Pre-eclampsia was less likely among women living with HIV on ART (AOR=0.26, 95% CI=0.07, 0.99), married (AOR=0.15, 95% CI=0.03, 0.71), and multiparous (AOR=0.16, 95% CI=0.03, 0.80).
high-sensitivity C-reactive protein levels were higher among the cases than controls. However, similar levels were observed in the subgroup of women living with HIV on ART. Participants with high hs-CRP levels had the highest odds of preeclampsia, suggesting that hs-CRP may be useful in predicting preeclampsia.
子痫前期影响估计 8%的孕妇,占全球产妇死亡人数的 12%以上。高敏 C 反应蛋白(hs-CRP)是子痫前期的潜在标志物。然而,关于赞比亚子痫前期妇女的 hs-CRP 水平知之甚少。本研究检测了与对照组相比,患有子痫前期的妇女(病例)和无子痫前期的妇女(对照组)的 hs-CRP 水平是否存在差异,包括是否患有 HIV 的亚组。
2022 年 2 月至 5 月期间,在妇女和新生儿医院进行了一项病例对照研究,共纳入 40 名患有子痫前期的孕妇(病例)和 40 名血压正常的孕妇(对照组),包括(n=20)和不患有 HIV(n=20)。采用标准 ELISA 试剂盒测定 hs-CRP 水平。条件逻辑回归模型计算了 hs-CRP 和其他预测变量的比值比及其 95%置信区间。
与对照组相比,病例组的 hs-CRP 中位数水平更高(7.84mg/ml vs 6.13mg/ml,p<0.001)。接受抗逆转录病毒治疗(ART)的 HIV 阳性子痫前期妇女的 hs-CRP 水平与 HIV 阴性妇女相似(7.92mg/ml vs 7.17mg/ml,p=0.862)。另一方面,接受 ART 的 HIV 阳性正常血压妇女的 hs-CRP 水平与 HIV 阴性妇女不同(6.60mg/ml vs 3.96mg/ml,p<0.001)。多变量条件逻辑回归显示,调整了显著预测因素后,hs-CRP 水平较高的孕妇(AOR=1.01,95%CI=1.01,1.01)更有可能患有子痫前期。接受 ART 的 HIV 阳性妇女(AOR=0.26,95%CI=0.07,0.99)、已婚妇女(AOR=0.15,95%CI=0.03,0.71)和多产妇(AOR=0.16,95%CI=0.03,0.80)患子痫前期的可能性较小。
与对照组相比,病例组的 hs-CRP 水平更高。然而,在接受 ART 的 HIV 阳性妇女亚组中观察到了相似的水平。hs-CRP 水平较高的参与者患子痫前期的几率最高,这表明 hs-CRP 可能有助于预测子痫前期。